...
首页> 外文期刊>Expert review of medical devices >The intraocular lens: challenges in the prevention and therapy of infectious endophthalmitis and posterior capsular opacification
【24h】

The intraocular lens: challenges in the prevention and therapy of infectious endophthalmitis and posterior capsular opacification

机译:人工晶状体:传染性眼内炎和后囊混浊预防和治疗方面的挑战

获取原文
获取原文并翻译 | 示例
           

摘要

Cataract is the leading cause of visual impairment worldwide. In the UK, some 30% of the population over 65 years of age have visually impairing cataract. Importantly, 88% of those with treatable visual impairment from cataract are not in contact with any ocular healthcare service, representing a major potential healthcare need m. In the USA, it has been estimated that 17.2% of the population (approximately 20.5 million) over 40 years of age have cataract in either eye and by 2020, this number is expected to rise to 30.1 million. Currently, cataract is responsible for 60% of Medicare costs associated with vision (2). Furthermore, as the populations of industrialized countries such as the UK and the USA continue to age, the costs associated with treatment of cataract can only be expected to increase. Consequently, the development of the intraocular lens to replace the cataractous lens and the advances in intraocular lens design and implantation represent a major development in cataract treatment. However, despite such advances, cataract surgery is not without complications, such as postoperative infectious endophthalmitis, a rare but potentially devastating condition, and posterior capsular opacification, a less serious but much more common problem. This review will examine the epidemiology of cataracts, the polymeric construction of intraocular lenses implanted during cataract surgery and the complications of postoperative infectious endophthalmitis and posterior capsular opacification with regard to therapeutic interventions and prophylactic strategies. Advances in biomaterial design and function will be discussed as novel approaches to prevent such postoperative complications.
机译:白内障是全世界视力障碍的主要原因。在英国,年龄在65岁以上的人口中约有30%患有视力受损的白内障。重要的是,88%的白内障可治愈的视力障碍患者未与任何眼保健服务机构接触,这代表了潜在的主要医疗保健需求。在美国,据估计,40岁以上人口中有17.2%(大约2,050万)的两只眼睛患有白内障,到2020年,这一数字预计将增加到3010万。目前,白内障负责与视力有关的医疗保险费用的60%(2)。此外,随着工业化国家(例如英国和美国)的人口不断老龄化,与白内障治疗相关的费用只能预期增加。因此,代替白内障晶状体的人工晶状体的发展以及人工晶状体设计和植入的进步代表了白内障治疗的主要发展。然而,尽管取得了这样的进步,但白内障手术并非没有并发症,例如术后感染性眼内炎是一种罕见的但可能具有破坏性的疾病,后囊混浊是一个不太严重但普遍得多的问题。这篇综述将探讨白内障的流行病学,在白内障手术期间植入的人工晶状体的聚合物结构以及术后感染性眼内炎和后囊膜混浊的并发症,涉及治疗干预和预防策略。生物材料设计和功能的进展将作为预防此类术后并发症的新方法进行讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号